THE ROLE OF GALECTIN-9 IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND ITS CONNECTION WITH THE TYPE OF THERAPY, THE DEGREE OF FIBROSIS, CLINICAL, LABORATORY, AUTOIMMUNE AND INTEGRATIVE INDICATORS

The aim: To establish the dependence of the concentration of galectin-9(CGal-9) in the serum of patients with chronic viral hepatitis C (CVHC) on the type of antiviral therapy (AVT), clinical-laboratory, autoimmune and integrative parameters, non-invasive methods of assessing the degree of fibrosis. Materials and methods: CGal-9 in serum were determined in 68 patients with CVHC and 20 healthy individuals, and clinical-laboratory and integrative parameters, noninvasive methods for assessing the degree of fibrosis were studied. Results:There were three groups: baseline (I), pegylated interferon (PEG-IFN) with ribavirin (II), velpatasvir with sofosbuvir (III). In pations from group I, compared with healthy people, CGal-9 was 1.7 times higher (p <0.05); in patients from group II it was 4.2 times higher (p<0.05); in patients from group III it did not differ from healthy individuals. All patients had a directly proportional correlation between CGal-9 and the frequency of splenomegaly detection; in patients who did not receive AVT, directly proportional – with De Ritis ratio, non-invasive methods of liver fibrosis, inversely proportional – with platelet count (p<0,05). There was a higher probability of positive indicators of antinuclear antibodies (ANA) at 12 weeks of treatment with PEG-IFN and ribavirin, with higher CGal-9 at 4 weeks of AVT (p<0,05). Conclusions: Correlations between CGal-9 and the frequency of splenomegaly detection, platelet count, De Ritis ratio, degree of lever fibrosis in correlation with METAVIR, APRI, FIB-4, ANA, NI were determined. The possibility of predicting the occurrence of splenomegaly, liver cirrhosis and positive ANA in patients with CVHC has been proven.

Download Full-text

MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C

International Medical Journal ◽

10.37436/2308-5274-2020-1-16 ◽

2020 ◽

pp. 72-75

Author(s):

O. P. Shevchenko-Makarenko ◽

L. R. Shostakovych-Koretska ◽

V. E. Dosenko ◽

T. I. Drevytska

Keyword(s):

Gene Expression ◽

Hepatitis C ◽

Viral Hepatitis ◽

Biological Marker ◽

Chronic Viral Hepatitis ◽

Expression Level ◽

Healthy Individuals ◽

Hcv Genotype ◽

Viral Hepatitis C ◽

Chronic Viral Hepatitis C

New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis. Key words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.

Download Full-text

POSSIBILITIES OF BIORREGULATION IN COMPLEX THERAPY OF CHRONIC PANCREATITIS IN COMORBIDITY WITH CHRONIC VIRAL HEPATITIS C

Fitoterapia ◽

10.33617/2522-9680-2021-1-28 ◽

2021 ◽

Vol 1 (1) ◽

pp. 28-34

Author(s):

L.S. Babinets ◽

◽

O.R. Schaygen ◽

Keyword(s):

Chronic Pancreatitis ◽

Hepatitis C ◽

Viral Hepatitis ◽

Conventional Treatment ◽

Chronic Viral Hepatitis ◽

Latent Stage ◽

Group I ◽

Viral Hepatitis C ◽

Complex Therapy ◽

Chronic Viral Hepatitis C

Key words: chronicpancreatitis, chronicviralhepatitis C, bioregulatorydrugs, Momordica compositum, Hepel, functional and structuralstate of the pancreas. Topicality. Insufficient development of primary and secondary prevention of chronic pancreatitis (CP), which occurs on the background of chronic viral hepatitis C (CVHC), requires a deeper study of the mechanism of its development and the establishment of clinical and pathogenetic features, which should be taken into account rehabilitation. One of such approaches to complex treatment of CP on the background of CVHC is the inclusion of drugs of bioregulatory therapy, which motivated thestudy. The aim is to investigate the parameters of the functional and structural state of the pancreas in chronic pancreatitis on the background of chronic viral hepatitis C, as well as their dynamics under the influence of complex therapy with the inclusion of bioregulatory drugs (BRD). Materials and methods. 106 patients with CP without exacerbation in combinationwith CVHC in the remission phase and without it were examined. The main group of the study included 72 patients with CP in the phase of unstable remission with concomitant CVHC in the latent stage. Patients with CP and concomitant CVHC were divided into two groups according to correction programs. It should be noted that patients in the study contingent of etiological antiviral therapy for CVHC infection for various reasons were not treated (refusal of antiviral treatment due to allergic history, personal intolerance, financial insolvency, etc.). Group I (36 patients) received only conventional treatment (CT). Group II (36 patients), in addition to CT, received additional BRD Momordica compositum for 1 amp. in / m 3 times a week for one month) and Hepel 1 tab. sublingually 3 times a day for 15-20 minutes before meals or after 1 hour after meals for one month. Results. After treatment an improvement in the structure of the pancreas and liver was observed, as evidenced by a decrease in the severity of Echoelastography and ultrasound. The score of ultrasound soft ware in the first group decreased by 28.6 %, and in the second group – decreased by 57.1 %; the rate of Echoelastography of the pancreas by 4.8% and 26.1 %, respectively, and the Echoelastography of the liver – by 15.3 % and 30.7 %, respectively. They also noted an improvement in the results of the coprogram and an increase in the level of fecal elastase-1: inthefirst group – by 23.8 %, and in the secondgroup – by 52.7 %. Discussion. Positive dynamics wasobserved in both groups, but in patients of group I after treatment it was less significant thaningroup II, where additionally a patient with CP on the background of CVHC received complex BRD (p <0.05). This proved a statistically significant higher efficacy of treatment using a complex bioregulatory corrector ofexocrine insufficiency (Momordica Compositum) and a complex bioregulatory hepatotropic drug (Hepeel) for one month. Conclusions: 1. Concomitant CVHC in the latent stage worsened the structural and functional state of the pancreas in CP, as well as the structural state of the liver according to EHR (p<0,05); 2. The use of complex bioregulatory therapy in addition to the conventional treatment of CP on the background of latent CVHC contributed to a statistically significant increase in its effectiveness in relation to conventional treatment: the level of fecal elastase-1 increased by 52.7% (p <0.05) compared to 23.8 %, pancreatic rigidity decreased by 26.1 % vs. 4.8 % (p <0.05), liver rigidity decreased by 30.7 % vs. 15.3 % (p <0.05).

Download Full-text

Possibilities of non-invasive determination of the stage of liver fibrosis in patients with chronic viral hepatitis C and metabolic syndrome

Infekcionnye bolezni ◽

10.20953/1729-9225-2018-3-46-50 ◽

2018 ◽

Vol 16 (3) ◽

pp. 46-50

Author(s):

D.Yu. Konstantinov ◽

◽

A.F. Novikova ◽

G.V. Nedugov ◽

A.A. Suzdaltsev ◽

...

Keyword(s):

Metabolic Syndrome ◽

Hepatitis C ◽

Liver Fibrosis ◽

Viral Hepatitis ◽

Chronic Viral Hepatitis ◽

Non Invasive ◽

Viral Hepatitis C ◽

Chronic Viral Hepatitis C

Download Full-text

HEPATOCELLULAR CARCINOMA

The Professional Medical Journal ◽

10.29309/tpmj/2016.23.04.1499 ◽

2016 ◽

Vol 23 (04) ◽

pp. 415-421

Author(s):

Amin Fahim ◽

Mohammad Ahmed Azmi ◽

Muhammad Hanif ◽

Anila Qureshi

Keyword(s):

Hepatitis C ◽

Viral Hepatitis ◽

Medical Center ◽

Cross Sectional Study ◽

Chronic Viral Hepatitis ◽

Etiologic Agent ◽

Cross Sectional ◽

Group I ◽

Viral Hepatitis C ◽

Chronic Viral Hepatitis C

Objectives: To determine the expression of miR-92-1 in HCC patients and correlatethem with clinicopathological data. Study Design: A Cross sectional study. Place of Study:Samples were collected from Jinnah Postgraduate Medical Center Karachi, Civil HospitalKarachi and Asian Institute of Medical Sciences Hyderabad. Duration of Study: January2014 to December 2014. Materials and Methods: 150 patients of hepatocellular carcinomawere divided into two groups on the basis of etiologic agent. HCC patients with chronic viralhepatitis B were labeled as group-I, whereas those with chronic viral hepatitis C in group-II,compared with 75 healthy control individuals in group-III. Results: The results showed thatmiR-92-1 expression was decreased in patients with HCC when compared with controls. Downregulation was seen more pronounced in HCC cases with chronic viral hepatitis C. A significantcorrelation was found between the expression of miR-92-1 and AFP level 20-200 ng/ml andChild Pugh score B. However no correlation was found between the expression of miR-92-1and age, gender, fibro scan, tumor distribution, tumor size, tumor metastasis and BCLC stage.Conclusion: miR-92-1 is down regulated in HCC patients with significant correlation with serumAFP level between 20-200 ng/ml.

Download Full-text